Study Using CP-461 to Treat Advanced Prostate Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male 18 years of age.
Histologically confirmed adenocarcinoma of the prostate, stage D1 or D2.
Failure of androgen ablation (orchiectomy or LHRH, flutamide).
Patients must have PSA progression and progression in measurable disease.
No prior history of systemic chemotherapy.
No investigational drugs within 4 weeks of study entry.
No radiation therapy or hormonal therapy within 4 weeks of study entry.
No isotope therapy within 6 weeks of study entry.
No antiandrogens within 4 weeks of study entry. Patients must continue LHRH.
If patients had prior surgery, it must be at least 21 days prior to study entry, and the patient must have recovered from all side effects.
Patients must have stopped bisphosphonates 28 days prior to study entry.
No prior malignancy allowed except for adequately treated basal cell or squamous cell skin cancer, or adequately treated stage I or II cancer from which the patient is currently in remission, and has been disease free for at least 5 years.
Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator not have significant active concurrent medical illness, such as a history of significant neurologic or psychiatric disorders including psychotic disorders, dementia, or seizures that would preclude protocol treatment or survival.
All patients must be informed of the investigational nature of the study and must sign and give written informed consent in accordance with institutional and federal guidelines.
No other chemotherapeutic, biological response modifiers, radiation therapy, corticosteroid therapy, or hormonal concomitant therapy (except continuation of LHRH) may be given during treatment. Patients should not be planning on receiving concomitant bisphosphonates.